J M Gallo

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. doi request reprint Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
    Shining Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    Mol Cancer Ther 7:407-17. 2008
  2. ncbi request reprint Population pharmacokinetic model for topotecan derived from phase I clinical trials
    J M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 18:2459-67. 2000
  3. ncbi request reprint The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:5114-7. 2003
  4. ncbi request reprint Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470
    J Ma
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 61:5491-8. 2001
  5. ncbi request reprint Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies
    G R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 6:3071-80. 2000
  6. ncbi request reprint Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 19:1183-94. 2001
  7. ncbi request reprint Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model
    P Guo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 48:169-76. 2001
  8. ncbi request reprint Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer
    Weijing Sun
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 8:3100-4. 2002
  9. ncbi request reprint Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:257-65. 2002
  10. ncbi request reprint Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice
    Gary D Kruh
    Medical Science Division, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Metastasis Rev 26:5-14. 2007

Collaborators

Detail Information

Publications23

  1. doi request reprint Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
    Shining Wang
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    Mol Cancer Ther 7:407-17. 2008
    ..The novel concept of PK/PD equivalent dosing regimens could be applied in drug development and to delineate PG differences in drug activity...
  2. ncbi request reprint Population pharmacokinetic model for topotecan derived from phase I clinical trials
    J M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 18:2459-67. 2000
    ..To characterize the pharmacokinetics of topotecan in a population model that would identify patient variables or covariates that appreciably impacted on its disposition...
  3. ncbi request reprint The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:5114-7. 2003
    ..It is concluded that even in the neovasculature of brain tumors, Pgp has the facility to limit drug penetration, although somewhat less so than in normal brain...
  4. ncbi request reprint Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470
    J Ma
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 61:5491-8. 2001
    ..It is increasingly important to understand the pharmacokinetic and pharmacodynamic behavior of each class of drug so that optimal dosing regimens can be designed...
  5. ncbi request reprint Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies
    G R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 6:3071-80. 2000
    ..o. three times daily is well tolerated on a 14-day on/14-day off dosing schedule. Inhibition of p21ras function in humans is not likely to occur after POH administration at safe doses of the present oral formulation...
  6. ncbi request reprint Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy
    R J Schilder
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 19:1183-94. 2001
    ..This approach remains experimental and should be used only in the context of a clinical trial...
  7. ncbi request reprint Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model
    P Guo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 48:169-76. 2001
    ..This type of target selectivity would allow higher tumor concentrations to be achieved in conjunction with lower drug concentrations in normal or non-target tissues...
  8. ncbi request reprint Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer
    Weijing Sun
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 8:3100-4. 2002
    ..Four patients exhibited disease stability after two cycles of treatment. CP-461 is minimally toxic at doses up to 800 mg/day when administered p.o. on a twice-daily schedule...
  9. ncbi request reprint Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:257-65. 2002
    ..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...
  10. ncbi request reprint Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice
    Gary D Kruh
    Medical Science Division, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Metastasis Rev 26:5-14. 2007
    ..This review will discuss insights into the physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 afforded by investigations of these new mouse models...
  11. pmc Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry
    Ping Guo
    School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    J Pharm Biomed Anal 43:1789-95. 2007
    ..The method has the advantages of low sample volume, rapid clean-up, and the simultaneous measurement of MTX and 7-OH MTX in plasma and brain tissues allowing detailed PK studies to be completed in individual mice...
  12. ncbi request reprint Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 N Broad St, Philadelphia, PA 19140, USA
    J Pharmacol Exp Ther 321:265-75. 2007
    ..In conclusion, several PK/PD factors contributing to the antitumor activity of the MD TMZ therapy have been identified and form a foundation for further investigations of low-dose TMZ regimens...
  13. ncbi request reprint Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
    Clin Cancer Res 13:4271-9. 2007
    ..Our goal was to show how the latter could be achieved for temozolomide, an agent used in the treatment of brain tumors, using an orthotopic brain tumor model in rats...
  14. ncbi request reprint Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage
    Martin G Belinsky
    Medical Science Division, Department of Pathology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer Res 67:262-8. 2007
    ..This is the first demonstration that an ATP-binding cassette transporter can affect in vivo tissue sensitivity towards this class of agents...
  15. pmc In vivo microdialysis for PK and PD studies of anticancer drugs
    Qingyu Zhou
    Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad Street, Philadelphia, PA 19140, USA
    AAPS J 7:E659-67. 2005
    ....
  16. ncbi request reprint Pharmacokinetic model-predicted anticancer drug concentrations in human tumors
    James M Gallo
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19140, USA
    Clin Cancer Res 10:8048-58. 2004
    ..It is believed that this modeling strategy can be used as an aid in the drug development process by providing key insights into drug disposition in tumors and by offering a foundation to optimize drug regimen design...
  17. ncbi request reprint Population pharmacokinetics of cisplatin in adult cancer patients
    Felix E de Jongh
    Department of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 54:105-12. 2004
    ..To characterize the pharmacokinetics of the anticancer agent cisplatin, and explore the influence of patient covariates and interoccasion variability on drug disposition...
  18. pmc Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
    Ramsis K Benjamin
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:65-74. 2004
    ..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials...
  19. ncbi request reprint Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometry
    Ping Guo
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 798:79-86. 2003
    ..054 to 1.96 microg/ml in brain homogenates. A sensitive and specific assay for paclitaxel has been developed that has the advantages of using small sample sizes, and a single extraction step without solvent evaporation...
  20. ncbi request reprint Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors
    Giuseppe Trapani
    Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
    Bioconjug Chem 14:830-9. 2003
    ..A plausible degradation pathway accounting for the available experimental data is presented...
  21. ncbi request reprint Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support
    Meiyu Shen
    Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:243-50. 2002
    ..In addition, single-sample and two-sample limited sampling models (LSMs) were derived to estimate carboplatin's AUC that could be used in the design of drug dosing regimens...
  22. ncbi request reprint Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance
    Jianguo Ma
    Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Biochem Pharmacol 63:1219-28. 2002
    ....
  23. ncbi request reprint Cells designed to deliver anticancer drugs by apoptosis
    Jianguo Ma
    Department of Pharmacology Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 62:1382-7. 2002
    ..Apoptosis-induced drug delivery offers a new avenue for targeted drug delivery research that uses biological control mechanisms...